Literature DB >> 26835296

How to assess minimal residual disease in pediatric and adult acute myeloid leukemia?

Gerrit J Schuurhuis1, Jacqueline Cloos1, Gert J Ossenkoppele1.   

Abstract

Entities:  

Year:  2013        PMID： 26835296      PMCID： PMC4728920          DOI： 10.3978/j.issn.2224-4336.2013.04.09

Source DB:  PubMed          Journal:  Transl Pediatr        ISSN： 2224-4336


× No keyword cloud information.
  13 in total

1.  Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.

Authors:  Jeffrey E Rubnitz; Hiroto Inaba; Gary Dahl; Raul C Ribeiro; W Paul Bowman; Jeffrey Taub; Stanley Pounds; Bassem I Razzouk; Norman J Lacayo; Xueyuan Cao; Soheil Meshinchi; Barbara Degar; Gladstone Airewele; Susana C Raimondi; Mihaela Onciu; Elaine Coustan-Smith; James R Downing; Wing Leung; Ching-Hon Pui; Dario Campana
Journal:  Lancet Oncol       Date:  2010-05-05       Impact factor: 41.316

2.  The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse.

Authors:  C Bachas; G J Schuurhuis; Y G Assaraf; Z J Kwidama; A Kelder; F Wouters; A N Snel; G J L Kaspers; J Cloos
Journal:  Leukemia       Date:  2012-01-13       Impact factor: 11.528

3.  Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia.

Authors:  T Flohr; A Schrauder; G Cazzaniga; R Panzer-Grümayer; V van der Velden; S Fischer; M Stanulla; G Basso; F K Niggli; B W Schäfer; R Sutton; R Koehler; M Zimmermann; M G Valsecchi; H Gadner; G Masera; M Schrappe; J J M van Dongen; A Biondi; C R Bartram
Journal:  Leukemia       Date:  2008-01-31       Impact factor: 11.528

Review 4.  Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008.

Authors:  M Brüggemann; A Schrauder; T Raff; H Pfeifer; M Dworzak; O G Ottmann; V Asnafi; A Baruchel; R Bassan; Y Benoit; A Biondi; H Cavé; H Dombret; A K Fielding; R Foà; N Gökbuget; A H Goldstone; N Goulden; G Henze; D Hoelzer; G E Janka-Schaub; E A Macintyre; R Pieters; A Rambaldi; J-M Ribera; K Schmiegelow; O Spinelli; J Stary; A von Stackelberg; M Kneba; M Schrappe; J J M van Dongen
Journal:  Leukemia       Date:  2009-12-24       Impact factor: 11.528

5.  High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine.

Authors:  Costa Bachas; Gerrit Jan Schuurhuis; Iris H I M Hollink; Zinia J Kwidama; Bianca F Goemans; C Michel Zwaan; Marry M van den Heuvel-Eibrink; Eveline S J M de Bont; Dirk Reinhardt; Ursula Creutzig; Valerie de Haas; Yehuda G Assaraf; Gertjan J L Kaspers; Jacqueline Cloos
Journal:  Blood       Date:  2010-06-30       Impact factor: 22.113

6.  Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples.

Authors:  J Cloos; B F Goemans; C J Hess; J W van Oostveen; Q Waisfisz; S Corthals; D de Lange; N Boeckx; K Hählen; D Reinhardt; U Creutzig; G J Schuurhuis; Ch M Zwaan; G J L Kaspers
Journal:  Leukemia       Date:  2006-04-27       Impact factor: 11.528

Review 7.  Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia.

Authors:  Francesco Buccisano; Luca Maurillo; Maria Ilaria Del Principe; Giovanni Del Poeta; Giuseppe Sconocchia; Francesco Lo-Coco; William Arcese; Sergio Amadori; Adriano Venditti
Journal:  Blood       Date:  2011-10-28       Impact factor: 22.113

8.  Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors.

Authors:  Panagiotis D Kottaridis; Rosemary E Gale; Stephen E Langabeer; Marion E Frew; David T Bowen; David C Linch
Journal:  Blood       Date:  2002-10-01       Impact factor: 22.113

9.  Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia.

Authors:  Hiroto Inaba; Elaine Coustan-Smith; Xueyuan Cao; Stanley B Pounds; Sheila A Shurtleff; Kathleen Y Wang; Susana C Raimondi; Mihaela Onciu; Jeffrey Jacobsen; Raul C Ribeiro; Gary V Dahl; W Paul Bowman; Jeffrey W Taub; Barbara Degar; Wing Leung; James R Downing; Ching-Hon Pui; Jeffrey E Rubnitz; Dario Campana
Journal:  J Clin Oncol       Date:  2012-09-10       Impact factor: 44.544

10.  Treating childhood acute lymphoblastic leukemia without cranial irradiation.

Authors:  Ching-Hon Pui; Dario Campana; Deqing Pei; W Paul Bowman; John T Sandlund; Sue C Kaste; Raul C Ribeiro; Jeffrey E Rubnitz; Susana C Raimondi; Mihaela Onciu; Elaine Coustan-Smith; Larry E Kun; Sima Jeha; Cheng Cheng; Scott C Howard; Vickey Simmons; Amy Bayles; Monika L Metzger; James M Boyett; Wing Leung; Rupert Handgretinger; James R Downing; William E Evans; Mary V Relling
Journal:  N Engl J Med       Date:  2009-06-25       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.